GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (MEX:BIIB) » Definitions » Institutional Ownership

Biogen (MEX:BIIB) Institutional Ownership : 68.49% (As of Jul. 15, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Biogen Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Biogen's institutional ownership is 68.49%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Biogen's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Biogen's Float Percentage Of Total Shares Outstanding is 88.62%.


Biogen Institutional Ownership Historical Data

The historical data trend for Biogen's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Institutional Ownership Chart

Biogen Historical Data

The historical data trend for Biogen can be seen below:

2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31 2024-06-30
Institutional Ownership 67.52 64.79 64.97 69.73 69.09 67.77 69.53 68.63 68.69 68.49

Biogen Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Biogen (MEX:BIIB) Business Description

Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (MEX:BIIB) Headlines

From GuruFocus

Q1 2022 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Biogen Inc Investor Day Transcript

By GuruFocus Research 01-22-2024

Biogen Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-22-2024

Biogen Inc at Cowen Health Care Conference Transcript

By GuruFocus Research 01-22-2024

Biogen Inc at Stifel CNS Days (Virtual) Transcript

By GuruFocus Research 01-22-2024

Q3 2023 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2023 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2021 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024